Merit Medical Systems Inc

Merit Medical Systems reported second-quarter 2026 revenue of $418.8 million, up 9.5% year over year and 3.5% above the Zacks Consensus Estimate, while adjusted earnings of $1.19 per share rose 18% and beat consensus by 23.9%. Organic revenue grew 9% at constant currency, with U.S. revenue up 11.5% and international revenue up 4.7%. Therapeutic revenue increased 15% on a reported basis, led by 24% growth in Cardiac Therapies and 29% growth in Endoscopy. Adjusted gross margin expanded 260 basis points to 55.8%, but excluding tariff refunds it was 54.2%, up 98 basis points, and management expects about $16 million of tariff costs in 2026. The company raised its 2026 adjusted earnings guidance to $4.25 to $4.35 per share from $4.01 to $4.15 and lifted its revenue range to $1.631 billion to $1.643 billion. MMSI trades at 20.3 times forward earnings versus 17.6 times for its Zacks sub-industry, and carries a Zacks Rank of 3, or Hold.

Merit Medical Systems announced that Sheri Lewis will join as Executive Vice President of Global Operations effective August 31, 2026. Lewis brings three decades of experience from senior roles at SkinHealth Systems, Avantor, Medtronic, and Honeywell. Current Chief Operating Officer Neil Peterson will become Senior Advisor to support the transition through March 5, 2027, after which he will leave Merit following more than 32 years with the company. President and CEO Martha G. Aronson said Lewis's experience will be important as Merit continues to scale globally.

Merit Medical Systems reported second-quarter results that exceeded analyst expectations and raised its full-year outlook. Revenue rose 9.5% year on year to $418.8 million, beating the consensus estimate of $405.3 million, while adjusted earnings per share of $1.19 came in 24% above the $0.96 forecast. The company lifted its full-year revenue guidance to $1.64 billion at the midpoint, up from $1.62 billion, and raised its adjusted EPS guidance to $4.30, a 5.4% increase. Organic revenue grew 9% year on year, and the adjusted operating margin improved to 14.4% from 12.3% a year earlier. Shares rose 5.1% to $87.73 following the announcement.

Merit Medical Systems is well-positioned for growth driven by its diversified product portfolio and continued R&D investment. The company launched the Resilience Through-the-Scope Esophageal Stent in the first quarter of 2026 and acquired View Point Medical, adding the OneMark Detection Imaging System and Tissue Markers to complement its SCOUT platform, which management believes expands its oncology addressable procedure opportunity roughly threefold. Merit Medical also reaffirmed its commercial strategy for the WRAPSODY Cell-Impermeable Endoprosthesis, expecting approximately $7 million in U.S. revenues in 2026. However, the company faces headwinds from tariffs, which management expects to remain a drag on profitability in 2026, and ongoing pricing pressure from China's volume-based procurement program. The Zacks Consensus Estimate for second-quarter 2026 revenues is $404.7 million, implying 5.81% growth, while the EPS estimate of 96 cents suggests a 4.9% decline from the prior year.

Merit Medical Systems reported first-quarter revenues of $381.9 million, up 7.5% year on year and exceeding analyst expectations by 1.2%. The company also beat earnings per share estimates and raised its full-year guidance, the highest raise among the four medical devices and supplies stocks tracked in the cardiology, neurology, and vascular segment. ICU Medical posted revenues of $525.8 million, down 12.3% year on year but still beating estimates by 1.2%, while Artivion's revenues grew 17.5% to $116.3 million but missed earnings estimates and provided weak guidance, sending its stock down 38.1%. Penumbra's revenues rose 15.6% to $374.8 million, topping estimates by 0.7%, though it missed earnings per share forecasts. Overall, the group's revenues beat consensus estimates by 0.9% on average, but share prices have fallen 6.2% since reporting.